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Bicuspidaorticvalve(BAV)isthemostcommoncongenitalheartdefect,aﬀecting1-2%ofthepopulation.Itisgenerallydiagnosed
late in adulthood when deterioration of the abnormal leaﬂet becomes clinically evident. BAV patients have an increased risk
of developing serious complications, including stenosis, regurgitation, endocarditis, dilation of the aorta, aortic dissection, and
aneurysm. BAV is a heritable trait, but the genetic basis underlying this cardiac malformation remains poorly understood. In the
last decade, thanks to studies in animal models as well as genetic and biochemical approaches, a large number of genes that play
importantrolesinheartdevelopmenthavebeenidentiﬁed.Thesediscoveriesprovidedvaluableinsightintocardiacmorphogenesis
and uncovered congenital-heart-disease-causing genes. This paper will summarize the current knowledge of valve morphogenesis
as well as our current understanding of the genetic pathways involved in BAV formation. The impact of these advances on human
health including diagnosis of BAV and prevention of cardiovascular complications in individuals with BAV or with a family history
of BAV is also discussed.
1. Overview of Valve Development
In human and other mammals, cardiac valves are essential
for unidirectional blood ﬂow which is crucial for proper
functioning and survival of the organism. Defects in valve
structure or function can profoundly alter cardiovascular
homeostasis and are among the leading causes of human
morbidity and mortality. Thus, understanding the molecular
basis of normal and pathologic valve development is of
utmost importance and clinical relevance. The valves of
the four chambered heart can be classiﬁed in 2 groups:
atrioventricular valves (mitral and tricuspid) separate the
atria from the ventricles while semilunar valves (aortic and
pulmonary) divide the ventricles from the great arteries.
Normal aortic valve is tricuspid, meaning it possesses three
leaﬂets(orcusps)butdefectivedevelopmentinvolvingfusion
of two of these produces bicuspid aortic valve (BAV). At 1-
2% prevalence in the human population, BAV is the most
common form of congenital heart disease and a signiﬁcant
risk factor for premature cardiovascular complications and
valve replacement in young adults.
In the embryo, the heart is the ﬁrst organ to develop
starting with the speciﬁcation and migration of the anterior
lateral plate mesoderm cells to form the cardiac crescent
[1]. This is closely followed (embryonic day (E) 8.5 in the
mouse and 3 weeks gestation in human) by migration of
the cardiac progenitors along the ventral midline where they
fuse to form a beating linear heart tube. This primitive tube
is composed of an inner endocardial cell layer separated by
the extracellular matrix (ECM), also known as the cardiac
jelly from the outer myocardial lining. At around E9.5 in the
mouse and 4-5 weeks in human, cardiac looping occurs and
brings the atrial region of the linear tube into a posterior
position to the common ventricle. At the same time,
increased production of ECM will cause the tissue to swell at
localized regions of the heart, initiating the formation of the
endocardial cushions at the atrioventricular (AV) canal and
outﬂow tract (OFT) [2, 3]. Endocardial cushion formation is
initiated by signals emanating from the AV canal and OFT
myocardium that will diﬀuse into the ECM and reach the
adjacent endocardial cells to undergo EMT. A large number
of transcription factors and signaling pathways have been
implicated in EMT and cushion morphogenesis, including
members of the TGF-β superfamily, VEGF, ErbB, NFATc1,
Notch, Wnt/β-catenin, Twist-1, Sox9, Tbx20, and Gata4,2 Cardiology Research and Practice
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Figure 1: Schematic representation of a bicuspid aortic valve. (a) Transverse section through the aorta showing a normal aortic valve with
three leaﬂets and their corresponding points of attachment to the aortic wall. A bicuspid aortic valve arises from fusion of two diﬀerent
cusps, resulting in the formation of a conjoined leaﬂet. (b) Schematic representation of the BAV subtypes. The R-N BAV arises from fusion
of the right coronary cusp and noncoronary cusp whereas the R-L BAV results from the fusion of the right coronary cusp and left coronary
cusp. LCA: left coronary artery; LCC: left coronary cusp; NCC: noncoronary cusp; RCA: right coronary artery; RCC: right coronary cusp.
and their function has been nicely described in a recent
review [4].
Endocardial cushion formation is a complex process that
relies on the transformation of a subpopulation of inner
endocardial cells into mesenchymal cells; this process termed
epithelial-to-mesenchymal transformation (EMT) occurs at
the AV canal boundary to initiate mitral and tricuspid
valve formation and, later, in the OFT to initiate aortic
and pulmonary valve formation. As development progresses,
these cushions will undergo exhaustive cell proliferation and
grow towards each other until they touch initiating a process
of fusion between the two cushions. Further remodeling of
the endocardial cushions results in the formation of thin
protruding leaﬂets composed of endocardial cells and ECM
that go on to form the valves. These last steps are dependent
on cell diﬀerentiation, apoptosis and ECM remodeling. In
the AV canal, EMT-derived mesenchymal cells are the sole
contributor to the mitral and tricuspid valves. In the OFT,
mesenchymalcellsoriginatingfrommigratingcardiacneural
crest cells will reach the OFT cushions and together with
endocardially derived mesenchymal cells will contribute to
the formation of the aortic and pulmonary valves. It is of
no surprise then that subtle perturbations in endocardial
cushion development can lead to heart valve diseases,
including bicuspid aortic valve (BAV). Of note, valve defects
are among the most frequent cardiovascular malformations
accounting for 25–30% [5].
In normal individuals, the aortic valve possesses three
leaﬂets, namely, the left coronary, the right coronary, and
noncoronary cusps, named after their relationship to the
coronary arteries (Figure 1). The morphology of the BAV
usually includes leaﬂets of unequal size as the result of the
fusion of two cusps, leaving one leaﬂet larger than the other
[6]. In humans, the larger leaﬂet is characterized by a raphe,
which is a thin ridge of tissue that represents the location
where the two cusps fused during valve development. In
addition, leaﬂet orientation has been shown to vary widely
among patients. The most frequent BAV subtypes are those
with fusion of the right and left (R-L) coronary leaﬂet,
representing 59% of cases and those with union of the right
and noncoronary (R-N) leaﬂet occurring in 37% of BAV
cases [7]. Insight into the etiology of the R-N and R-L
BAVs was further gained from studies of Nos3 null mice as
well as the inbred Syrian hamsters strain which selectively
display R-N and R-L subtypes, respectively [8, 9]. These
studies suggested that the R-N BAV is caused by defective
formation of the OFT cushion whereas the R-L BAV is likely
the result of defective OFT septation. Thus, the two BAV
subtypes appear to have distinct etiologies. In addition, it has
been shown that the R-N fusion is associated with increased
dimensionsoftheaorticrootaswellasdevelopmentofaortic
insuﬃciency later in life [10, 11]. The R-L fusion, on the
other hand, is associated with a more rapid progression to
valvedysfunctionandincreaseddimensionoftheaorticarch.
A new technique, called 3D time resolved phase contrast
cardiac magnetic resonance (4D Flow), has been described
recently as a powerful tool to allow a better characterization
of aortic-valve-related ﬂow dynamics as well as progression
of aortic dilation in patients with BAVs [11]. In this study,
Hope et al. demonstrated a signiﬁcant elevation of ascending
aortic wall shear stress in a subgroup of patients with BAVs,
the majority of whom had R-L fusion. Shear stress to the
aortic wall has been linked to aortic aneurysm formation,
thus this technique provides a noninvasive mean to quantify
the increased blood ﬂow through the ascending aorta in
patients with BAVs even before there is a clear manifestation
of aortic aneurysms.
2. Insightsfrom HumanGenetics
Information regarding prevalence of human BAVs has been
acquired through autopsy and echocardiographic studies.Cardiology Research and Practice 3
BAV is now believed to be the most common cardiovascular
malformation with a prevalence of 1-2% in the general
population [12]. Even though BAV is usually an isolated
defect, it may be associated with other cardiovascular syn-
dromes or malformations with at least one-third of patients
likely to develop serious complications that will require valve
surgery [13]. It is now clear that BAV is a risk factor for
adult cardiovascular events. These include aortic stenosis,
regurgitation, dissection, dilation/aneurysm as well as valve
calciﬁcation and infective endocarditis. In the last decade,
conﬂicting results have been obtained regarding the presence
of thoracic aortic aneurysms in the setting of BAVs [14].
Some groups have shown that there is a higher rate of
aortic root dilatation in individuals with BAVs while others
foundthoracicaorticaneurysmsinﬁrst-degreerelativeswith
normal tricuspid aortic valves. Thus, aortic aneurysms in the
context of a BAV may not exclusively be due to disturbed
blood ﬂow through the aortic valve. For example, Bunton
et al. have demonstrated that the ﬁbrilin-1 gene, which is
involved in Marfan syndrome, plays an important role in
maintaining the integrity of elastic ﬁbers and that mutations
inFIBRILIN-1coulddecreasetheelastincontentintheaorta,
providinganewmechanismforthepresenceofaneurysmsin
patients with Marfan syndrome [15]. A better understanding
of the molecular pathways that maintain the integrity of the
aorta is warranted in order to elucidate the pathogenesis of
aortic aneurysms in BAV patients.
SeveralstudiesaddressingtheheritabilityofBAVrevealed
high incidence of familial clustering [16–18]. Glick and
Roberts noted that 17 patients out of 71 family members
(24%)hadaorticvalvediseaselikelysecondarytoaBAV,with
2o rm o r ef a m i l ym e m b e r sa ﬀected. Using echocardiography
screening of 190 ﬁrst-degree relatives, Huntington and
colleagues reported a prevalence of BAV of 9.1% among the
ﬁrst-degree relatives, suggesting that the distribution of BAV
follows an autosomal dominant inheritance with reduced
penetrance [16]. Using a variance component methodology,
Cripe et al. found that, using their mathematical model, the
heritability of BAV was 89% suggesting that BAV is almost
entirely genetically determined and that mutations in diverse
genes with divergent inheritance pattern may be responsible
for BAV formation in diﬀerent families [19]. In conclusion,
epidemiologic studies suggest that BAV is heritable and
follows an autosomal dominant mode of transmission with
reduced penetrance and variable expressivity.
While the heritability of BAV is now well established,
genes linked to the defect remain largely unknown. A family-
based linkage analysis using microsatellite markers revealed
linkage to three loci on chromosome 18q, 5q, and 13q, but
the precise gene(s) within these regions were not deﬁned
[20]. To date, only mutations in NOTCH1, a gene that maps
to9q34-35,havebeenassociatedwithBAVinasmallnumber
of families (Table 1). Initially, a nonsense and a frameshift
mutation in two family members with BAV and valve
calciﬁcation were identiﬁed in a large family with 11 cases
of congenital heart disease, four of which required aortic
valve replacement [21]. Shortly thereafter, new undescribed
missense mutations were identiﬁed in patients with BAV
and/oraorticaneurysmsintwoindependentstudies[22,23].
These observations provided strong evidence that NOTCH1
haploinsuﬃciency can cause aortic valve disease.
Mutations in transcription factor GATA6 have been
associated with congenital heart defects, including tetralogy
of Fallot, persistent truncus arteriosus, and atrial septal
defects [24–26]. GATA6 is involved in OFT morphogenesis
and its deletion from neural crest cells in mice causes
perinatallethalityduetoaspectrumofaorticarchpatterning
and cardiac OFT septation defects [27]. Recently, Lin et al.
discovered that one of the parents of a patient with ASD had
aBAVsuggestingapossiblerelationship betweenGATA6and
BAV (Table 1). Interestingly, GATA6 maps to chromosome
18q, which is linked to BAV, but no mutations in the GATA6
gene have been reported yet in individuals with BAV [20]. Of
note, examination of the aortic valve of Gata6 heterozygote
mice revealed partial penetrance of BAVs (our unpublished
data) supporting a role for GATA6 as a candidate BAV-
causing gene.
Human genetics have also revealed that perturbations
in the expression of ECM components (elastin, collagen,
and proteoglycans) can lead to cardiac defects (Table 1). For
example, mutations in FBN1 (an extracellular glycoprotein
of the ECM that acts to maintain tissue elasticity of the
valve leaﬂets and aortic wall by linking smooth muscle cells
to adjacent elastin ﬁbrils) have been observed in patients
with Marfan syndrome (MFS), a genetic disorder of the
connectivetissuecharacterizedbymitralvalveprolapse,BAV,
and/or aortic dissection and aneurysm [28–30]. Moreover,
reduced expression of FBN1 in the aorta of patients with
BAVs was reported [31]. Of note, targeted deletion of
Fbn1 in mice phenocopies the defects observed in Marfan
syndrome indicative of a causal relationship between FBN1
mutations and valve malformation [32, 33]. These mice
haveupregulatedTGF-β signalling,mitralvalveprolapseand
die shortly after birth due to aortic dissection caused by
weakening of the aortic wall [34]. Interestingly, mutations
in the TGF-β receptors, TGFBR1 and TGFBR2,h a v eb e e n
associated with Marfan and Loeys-Dietz syndromes [35, 36].
Recently,amissensemutationinTGFβR2identicaltotheone
f o u n di nM F Sp a t i e n t sw h ot e s t e dn e g a t i v ef o rm u t a t i o ni n
FBN1 was found in a patient with BAV and aortic aneurysm
[37] but an earlier study found no mutation in either
TGFBR1 or TGFBR2 in patients with isolated BAV.
Aortic dilation, dissection, and/or aortic aneurysm are
the most common vascular complications in patients with
BAV. Linkage analysis of 7 family members with aortic
aneurysms and dissection, of whom three had BAVs iden-
tiﬁed ACTA2 which encodes smooth muscle α-actin [38].
Analysisofaortictissuefromthesepatientsshowedincreased
proteoglycans accumulation, fragmentation, loss of elastic
ﬁbers, and decreased numbers of smooth muscle cells,
consistent with aortic wall degeneration. However, whether
ACTA2 mutations cause BAV remains uncertain.
Other gene mutations have been linked to syndromic
disease that include aortic valve abnormalities. For example,
homozygous truncating mutations in HOXA1 have been
associated to Bosley-Salih-Alorainy syndrome and Athabas-
can Brainstem Dysgenesis syndrome [39]. Interestingly,
severe cardiovascular malformations, including interrupted4 Cardiology Research and Practice
Table 1: Human gene mutation and phenotype associated with bicuspid aortic valve formation.
Gene aﬀected Human syndrome Human cardiac
phenotype
Mutation and/or
expression in BAV
patients
Mouse valve phenotype Reference
NOTCH1
BAV, calciﬁcation,
BAV with aortic
aneurysm
R1108X, H1505del,
T596M, P179H,
A1343V, P1390T
Thick valve leaﬂets,
calciﬁcation [21–23]
GATA6 ASD, TOF Mother of the ASD
patient had a BAV
No valve phenotype
reported [26]
FBN1 Marfan syndrome Mitral valve prolapse,
Aortic aneurysm
Reduced expression
of FBN1
Thick and long valve
leaﬂets, mitral valve
prolapse
[28–31]
TGFBR2
Loeys-Dielz
syndrome, Marfan
syndrome
Mitral valve prolapse,
aortic aneurysm, BAV V387M
Defective remodelling of
the AV cushion, lethality
at E11.5 precluding
analysis of valves
[36]
ACTA2
Thoracic aortic
aneurysm and
dissection
Three family
members had a BAV No valve phenotype [38]
HOXA1
Bosley-Salih-Alorainy
syndrome, athabascan
brainstem dysgenesis
syndrome
Interrupted aortic
arch type B, aberrant
subclavian artery,
VSD, TOF, BAV
Not reported BAV [39]
KCNJ2 Andersen syndrome
BAV, BAV with
coarctation of the
aorta, pulmonary
stenosis
R67W Not reported [41]
ASD: atrial septal defect; BAV: bicuspid aortic valve; OFT: outﬂow tract; TOF: tetralogy of Fallot; VSD: ventricular septal defect.
aortic arch type B, aberrant subclavian artery, ventricular
septal defect, tetralogy of Fallot, and BAV, are observed in
these syndromes. Targeted inactivation of Hoxa1 in mice
was shown to recapitulate these defects [40]. Among cardiac
malformations, BAVs were obtained with a prevalence of
24%.ItremainstobeseenwhethermutationsinHOXA1will
be discovered in BAV patients.
Similarly,heterozygousmissensemutationsintheKCNJ2
potassium channel have been linked to Andersen syndrome
(Table 1)[ 41]. This rare disorder is characterized by prolon-
gation of the QT interval with ventricular arrhythmias, peri-
odic paralysis, dysmorphic facies, cleft palate, and scoliosis.
Additional features seen in the pedigree were cardiovascular
malformations, including BAV, BAV with coarctation of
the aorta, or pulmonary stenosis, which had never been
associated with this disease before. Whether this or another
as yet unidentiﬁed mutation causes BAV is unclear and
the link between defective potassium current and abnormal
aortic valve formation has not been investigated.
In summary, human genetics support the involvement of
multiple causative and modiﬁer genes in BAV inheritance.
The majority of these genes remain to be identiﬁed.
3. Insightsfrom AnimalModels
Over the past decade, analysis of aortic valves of genetically
engineered mice have provided important insight into valve
development and identiﬁed potential candidate genes that
could underlie BAV formation (Table 2). One of the ﬁrst
mouse models of BAV was reported in Nos3 null mice
who had a broad spectrum of CHD including BAV all
from the fusion of the right and noncoronary leaﬂet (R-N)
[9, 42]. Nos3 is expressed in endocardial cells of the heart
and is shear-stress-dependent [43]. Since formation of the
endocardial cushions depends on the EMT, a shear-stress
dependent process, Nos3 deﬁciency might alter endocardial
cell migration during EMT, causing abnormal development
of the valve cushion. Consistent with this, NOS3 expression
wasfoundtobesigniﬁcantlylowerinpatientswithBAV[44],
providing further support for the relevance of NOS3 and
possibly its regulators in BAV formation.
Members of the GATA family of transcription factors
such as the endothelially expressed GATA2 are transcription
activators of NOS3 [45]. Another member, GATA5, has
been shown to be restricted to endocardial cells and the
endocardialcushionsoftheAVcanalandOFT[46].Recently,
we generated a Gata5 null mouse model and found partial
penetrance of BAVs with a prevalence of 26% [47]. To gain
more insight into the role of Gata5 in endocardial develop-
ment including the cell type contributing to these defects, we
generated a conditional mouse model lacking Gata5 only in
endothelial cells (eGata5−/−). The eGata5 mutant mice had a
similar prevalence of BAVs as the Gata5 null mice suggesting
a cellautonomous function for Gata5 in endocardial cushion
development. Remarkably, in both mouse models, the BAV
was due to fusion of the right and noncoronary leaﬂets (R-
N BAV), identical to what was seen in the Nos3 null mice.
Reduced expression of Nos3 was observed in the endocardialCardiology Research and Practice 5
Table 2: Mouse models of bicuspid aortic valve formation.
Gene aﬀected Human cardiac
phenotype Mouse model Mouse valve
phenotype Cardiovascular expression Reference
Hoxa1 IAAB, ASC, VSD,
BAV, TOF Hoxa1−/− BAV
Neural crest cells, OFT
endocardium and
myocardium, Secondary
heart ﬁeld
[40]
NOS3 Not reported Nos3−/− BAV Endocardium, myocardium [42]
Gata5 Not reported Gata5−/− and Tie2Cre;
Gata5F/F BAV
Endocardium, AV and OFT
endocardial cushions,
subset of endocardial cells,
epicardium
[47]
Nkx2.5 ASD, AV block, VSD,
TOF, HCM
Nkx2.5GFPhet,
Nkx2.5HDneohet BAV, aortic aneurysm Myocardium [53]
ASC: aberrant subclavian artery; ASD: atrial septal defect; AV: atrioventricular; BAV: bicuspid aortic valve; HCM: hypertrophic cardiomyopathy; IAAB:
interrupted aortic arch type B; VSD: ventricular septal defect; TOF: tetralogy of Fallot.
cushions of the OFT in the Gata5 null mice. Together these
observations point to exquisite NOS3 dosage sensitivity in
aortic leaﬂet formation. In vitro studies demonstrated that
Gata5 is a potent activator of the Nos3 promoter suggesting
that NOS3 may be the downstream eﬀector of GATA5 in
endocardial cushion cells. Our studies also revealed that the
Notch pathway is signiﬁcantly downregulated in Gata5 null
and eGata5−/− mice. Of note, decreased expression of Jag1
the Notch ligand was observed in Gata5 null and eGata5−/−
mice with a concomitant upregulation of Rbpj-κ, the Notch
pathway repressor. Downregulation of the Notch pathway in
embryonicheartswasconﬁrmedbydecreasedimmunostain-
ing for the Notch1 intracellular domain (NCID). Together,
these observations suggest that reduced Notch1 activation
and subsequent Notch signaling in the outﬂow tract could
contribute to abnormal endocardial cushion formation and
fusion of the aortic valve leaﬂets. The Notch pathway plays
major roles in multiple developmental processes, including
cardiovascular development. Among others, it has been
shown to be critical for EMT, a key process for valve
formation. In mammals, the Notch family consists of 4
type I transmembrane receptors (Notch1 to 4) and 5 type
I transmembrane ligands, Jagged1, Jagged2, Delta-like (Dll)
1, Dll3, and Dll4 [48]. Upon ligand binding, a protease
complexcontaininggammasecretasecleavestheintracellular
domain of Notch, which enters the nucleus and regulates
gene expression through binding to the transcription factor
RBP-Jκ. It has been observed that Notch1 plays key roles
during valve development and EMT, consistent with its
expression pattern in the endocardium and OFT cushion
mesenchyme. Of note, Notch1 null mice die early due to
severe cardiac defects, including defective EMT [49]. In the
last couple of years, diﬀerent groups have tried to shed light
on the molecular mechanism of aortic valve calciﬁcation.
Nigam and Srivastava reported that inhibition of Bmp2
blocked calciﬁcation of murine aortic valves in vivo and
in vitro, suggesting that Notch1 represses Bmp2 within the
aortic valve [50]. In addition, Acharya et al. discovered that
inhibition of Notch1 in an in vitro model of aortic valve
calciﬁcation was prevented by the addition of Sox9, indicat-
ing that Notch1 regulates aortic valve calciﬁcation through
a Sox-9-dependent pathway [51]. In conclusion, all of these
ﬁndings demonstrate that NOTCH1 haploinsuﬃciency plays
a key role in valvulogenesis as well as the maintenance of
normal valve function in the adult heart. Expression of the
three cardiac GATA factors partially overlaps during cardiac
development. Our studies revealed that Gata4+/−Gata5+/−
and Gata5+/−Gata6+/− die embryonically or perinataly due
to profound cardiac defects including double outlet right
ventricles and ventricular septal defects [52]. Interestingly,
nearly half (3/7) Gata4+/−Gata5+/− mice had very high pres-
sure gradient through the aortic valve and examination of
the aortic valve of these mice revealed the presence of BAVs.
Similarly, we observed BAV in 25% (1/4) Gata5+/−Gata6+/−
embryos at E18.5 (unpublished data). These observations
are indicative of dosage sensitivity for cardiac GATA factors
in aortic valve formation. They also suggest that CHD-
causing genes might interact to inﬂuence CHD penetrance
andexpressivity including BAV.Theseresultshaveimportant
implications for human genetic studies.
BAVs have been reported in a small proportion (11%)
of mice haploinsuﬃcient for Nkx2.5 [53] ,ag e n et h a th a s
beenassociatedwithseveralhumanCHDs(Table 2).NKX2.5
maps to chromosome 5q34, which has been linked to BAVs,
and although one study did not ﬁnd any polymorphisms
in the coding region of Nkx2.5 in BAV patients [54], it still
remains to be determined whether mutations in the NKX2.5
gene will be discovered in future studies of human BAV.
Nkx2.5 is a critical regulator of cardiac morphogenesis and
wasshowntomodulateECMoftheaortathroughregulation
o fc o l l a g e nt y p eI[ 55]. Interestingly, mutations in collagen
type I have been linked to Ehlers-Danlos syndrome, which
is characterized by skin and bone abnormalities as well as
mitral and aortic valve dysfunction [56].
In conclusion, while the molecular basis of BAV is
incompletelyunderstood,atleast2pathwaysseemcriticalfor
normal tricuspid formation, namely, Notch and Nos3. This
information, together with the availability of mouse models6 Cardiology Research and Practice
of BAV, represents an important step in understanding the
pathogenesis of BAV and for studies aimed at the prevention
of BAV associated cardiovascular events.
4.IsBAV RelatedtoOther Congenital
HeartDefects?
In general most inherited congenital heart defects (CHDs)
show variable expressivity and penetrance including many
autosomaldominant syndromes. Asstated earlier, BAVs have
been identiﬁed in family members whose parents or siblings
had other CHDs. The availability of the Gata5 null mice
which do not have other structural heart defects besides
BAV oﬀers the unique possibility to genetically test the link
between BAV and other heart defects. This is easily achieved
by crossing with speciﬁc mouse strains. The ﬁrst set of exper-
iments aimed to explore the consequences of combinatorial
heterozygosityofGata5andthe2othercardiacGATAfactors,
GATA4 and GATA6, both of which have been linked to
human CHD including septal and valve defects [24, 26, 57–
59].
The resulting double hets oﬀsprings had multiple CHDs
and reduced survival suggesting that genes linked to BAVs
contribute to other cardiac defects. This information is
important for understanding the incidence of BAVs in con-
junction with other CHDs in families and for future human
genetic studies.
5 .W h e r eDoW eGof r o mH e r e ?
BAVs as well as other CHDs are complex multifactorial and
multigenetic diseases with variable expressivity and pene-
trance. Thus, not all family members with a similar gene
mutation will have the same heart disease and the same
mutation can cause diﬀerent CHDs in diﬀerent individuals.
These observations are consistent with the presence of mod-
ifying factors including genetic and environmental ones that
inﬂuence the phenotype [60]. Consistent with this, inﬂu-
ences of the genetic background on the phenotype is now
well documented in experimental animal models and in
humans [59, 61, 62]. Thus, analysis of upstream regulators,
interacting proteins as well as downstream targets of genes
known to be linked to BAV will likely identify new CHD-
causing or modiﬁer genes.
Moreover, understanding the progression of the disease
starting in childhood would help to slow down disease
progression and improve the timing of intervention of each
patient. In addition, BAV-linked genes have also been shown
to be involved in other adaptive responses of the heart. For
example, Notch1-deﬁcient mice subjected to pressure over-
load develop increased hypertrophy, ﬁbrosis and mortality
rate is increased, suggesting that Notch1 is important for
survival[63].Similarly,Gata5nullmicesubjectedtopressure
overload develop more cardiac conduction defects, have
increased ﬁbrosis, cardiac hypertrophy, and heart failure
(unpublished data).
Such studies combined with our ability to delete genes
in speciﬁc cells and at speciﬁc developmental states in ani-
mal models will undoubtedly unravel numerous candidate
CHD-causing genes that can be directly tested in human
genetic studies. Conversely loci identiﬁed through linkage
analysis in human cohorts can be tested in animal models
to conﬁrm (or not) their causative link to disease.
Additionally, the availability of animal models of BAV
and other valve disease will allow direct testing and identi-
ﬁcation of genetic modiﬁers as well as the molecular basis of
gene-environment interaction in BAV formation.
Lastly, BAV is a risk factor for early onset of serious
cardiovascular complications but the molecular basis and
tools (such as biomarkers) to monitor disease progression
remain largely undeﬁned.
The existing (and future) animal models of disease will
hugely facilitate such important analysis by allowing manip-
ulations of diets, of cardiovascular parameters such as vol-
ume and pressure overload, and of other aging-related alter-
ations. The results of such studies will undoubtedly be
translated into better diagnosis followup and prevention of
premature complications in individuals with family history
of valve disease.
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